Startups
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
Valo Health is the latest company to go public through a merger with a special purpose acquisition company. It will merge with Khosla Ventures Acquisition Co. and begin to trade on the Nasdaq.
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
Thanks to a recent joint venture, there is a new company taking on cancer and autoimmune diseases.
PRESS RELEASES